$FLXN On the watch for an entry
Thanks for the DD - very helpful!!!
I worked on the name early this morning and will look for an entry, but traders need to be willing to hold through P2B data. Data expected this month. We could see anytime now, management has a habit of under promising and over delivering, so next week is possible.
Institutional ownership is broad, but the big bio institutions are not really involved, very little activity of late.
$TRVN STRONG run on data will probably help FLXN if p2B data positive.
P2B trail hurdle rate is low and it's a large trial N=310,
Inclusion criteria for Q1p3 registration trial is the same as the P2B, so should be a good read through into the P3 data.
P3 trail target N=450 completed enrollment 3 months early and N=486, clinicians appear to be enthusiastic.
-BioHunter
-BioHunter
Twitter: @TheBio_Hunter
